Thread by @EricTopol

Big news: The JNJ vaccine results of 44,000 Phase 3 trial, a single dose. Overall 66% efficacy, with the contrast of 72% in US but 57% in South Africa, confirming immune escape/resistance of B.1.351 variant seen by Novavax

This news is certainly welcome, clearly fulfills FDA threshold and adds to the vaccine tool chest. It is a clear drop down from the 2-dose mRNA efficacy
statnews.com/2021/01/29/jj-… @matthewherper @statnews

I have to revise the #SARSCoV2 Variant table with latest information from past 12 hours

The JNJ @JanssenUS trial had 468 endpoints, the most infection events of any of the trials to date for assessment of efficacy, vaccine 85% effective vs severe events, and diversity of participants: 45% Latino, 19% Black, 9% Native American

So we now have 3 different types of vaccines with efficacy against #SARSCoV2: mRNA, protein, and adenovirus vectors. We've also seen failure of a major vaccine program @Merck. All of this in less than a year represents remarkable progress vs a very formidable challenge.

Very good synthesis of the 2 new vaccine trials, @Novavax and JNJ, by @Dereklowe
blogs.sciencemag.org/pipeline/archi…
💯Agree on the need to see data for protection of severe events, the intriguing potential of antibody maturation. Need for vaccine updates.